Changing treatment: latest news

Changing treatment resources

Changing treatment features

Changing treatment in your own words

Changing treatment news from aidsmap

More news

Changing treatment news selected from other sources

  • Sophisticated HIV diagnostics adapted for remote areas

    Diagnosing HIV and other infectious diseases presents unique challenges in remote locations that lack electric power, refrigeration, and appropriately trained health care staff. To address these issues, researchers have developed a low-cost, electricity-free device capable of detecting the DNA of infectious pathogens, including HIV-1.

    10 December 2014 | Science Daily
  • Effective treatments available for HIV patients not eligible for efavirenz regimens

    HIV drug regimens that do not include efavirenz are effective as first-line antiretroviral therapy, a new American clinical trial found. The finding is important for patients who are not eligible for treatment with efavirenz, including women considering becoming pregnant and patients with a history of severe psychiatric disorders.

    07 October 2014 | Science Daily
  • Switch From Efavirenz to Rilpivirine Quells CNS Toxicity, Improves Sleep

    Switching from Atripla (efavirenz plus tenofovir/emtricitabine [TDF/FTC]) to Complera (Eviplera, rilpivirine plus TDF/FTC) significantly relieved central nervous system (CNS) toxicity and improved sleep in people with those problems while taking Atripla [1]. All but 1 of 40 study participants who switched in this London/Brighton study maintained virologic control through 24 weeks.

    16 September 2014 | NATAP
  • Switch from single-tablet regimen to 3 tablets works in Denmark

    Switching from an efavirenz-containing single-tablet regimen (STR) to an efavirenz containing triple-tablet regimen (TTR) to save money maintained viral suppression in Denmark. Antiretroviral-naive people who started the TTR attained the same virologic suppression rate as people who started the STR combination.

    10 July 2014 | International AIDS Society
  • New ARV prescribing guidelines for London (2014)

    The guidelines are the result of a therapeutic tender, which encourages drug manufacturers to offer volume discounts for different stages of the treatment pathway, for example, for preferred use in first-line, second-line and multiple resistant treatment.

    01 July 2014 | HIV i-Base
  • Viral load rebounds in 35% of people using PI/r monotherapy: results of five-year PIVOT study

    A long-term strategy study sponsored by the Medical Research Council (MRC) in the UK reported low rates of serious complications and the potential to reduce drug costs. However, more than a third of people on the PI/r monotherapy group had viral load rebound compared to only 3% of people on standard combination therapy.

    10 March 2014 | HIV i-Base
  • U.S. FDA Approves Gilead’s Once-Daily Single Tablet HIV-1 Regimen Complera® for Patients Switching from a Stable Regimen

    European Commission Also Approves Expanded Indication for Regimen, Marketed as Eviplera® in the European Union.

    16 December 2013 | Gilead press release
  • Once-daily raltegravir for 48 weeks as maintenance therapy in Paris

    Sixty-eight of 71 people who switched to once-daily raltegravir with a viral load below 50 copies maintained virologic suppression for 48 weeks in an observational study at a Paris hospital. Virologic failure occurred in 3 people taking nucleos(t)ides with raltegravir who had a previous nucleos(t)ide failure.

    22 October 2013 | NATAP
  • TDF/FTC-to-ABC/3TC switch maintains viral suppression, eases bone markers

    A switch from tenofovir/emtricitabine (TDF/FTC) to abacavir/lamivudine (ABC/3TC), both with atazanavir/ritonavir, maintained viral suppression through 48 weeks in a noninferiority analysis and improved bone and kidney markers. Four people in the ABC/3TC arm (2%) and one in the TDF/FTC arm (1%) had study-defined virologic failure by week 48.

    19 September 2013 | NATAP
  • Switching From Efavirenz to Rilpivirine Combo Quells CNS Side Effects

    Swapping efavirenz-containing Atripla for rilpivirine-containing Complera (Eviplera in Europe) significantly lowered rates of central nervous system (CNS) side effects and sleep disturbances in a 40-person multicenter pilot trial.

    13 September 2013 | NATAP
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.